RESUMEN
The Pantanal region, the largest floodplain in the world, has a huge biodiversity and is an important livestock center. Bovine brucellosis has been reported in the region over the last three decades, posing implications for cattle industry as well as for the maintenance of biodiversity. We aimed to investigate the presence of B. abortus S19 vaccine strain DNA in unvaccinated domestic and wild ungulates from the Brazilian Pantanal. Fifty-two heifers, 63 ovine, 24 domestic pigs, 28 feral pigs, and three Pampas deer were sampled. Brucella spp. was detected through bcsp31 PCR of blood samples in 45.3% (77/170) of the sampled animals, of which 36.4% (28/77) showed positivity in ery PCR corresponding to B. abortus S19 strain. Feral pigs presented the highest occurrence of positive samples in bcsp31 PCR (75%), followed by ovine (47.6%), domestic pigs (41.7%), and unvaccinated heifers (30.8%). We did not observe positivity in Pampas deer. Our results strongly suggest that vaccination against bovine brucellosis may promote spill-over of B. abortus S19 strain in the Pantanal region. Moreover, our data indicate that wild strains of Brucella circulates in the Pantanal Biome.
Asunto(s)
Animales Salvajes , Brucelosis , ADN Bacteriano , Ciervos , Animales , Brasil , Brucelosis/veterinaria , Brucelosis/microbiología , Ciervos/microbiología , Ovinos , Animales Salvajes/microbiología , ADN Bacteriano/genética , Bovinos , Porcinos , Brucella abortus/genética , Brucella abortus/clasificación , Brucella abortus/inmunología , Brucella abortus/aislamiento & purificación , Vacuna contra la Brucelosis/genética , Vacuna contra la Brucelosis/inmunología , Animales Domésticos/microbiologíaRESUMEN
Brucellosis is a worldwide zoonotic disease caused by Brucella spp. and transmitted from domestic and wild animals to humans. Brucellosis causes important economic losses in livestock, has a significant impact on public health, and may affect the health of wildlife. Hunting and consumption of meat from culled wildlife constitute a risk for Brucella spp. infection in humans and hunting dogs. In El Palmar National Park (EPNP), Argentina, the invasive alien mammals wild boar (Sus scrofa) and axis deer (Axis axis) are controlled, slaughtered in situ, and consumed by hunters, with meat trimmings and offal often fed to dogs. In this study, we evaluated but did not detect anti-Brucella antibodies in wild boar (n=95) and axis deer (n=238) from EPNP or in game consumers, dogs (n=39) and humans (n=61). These results suggest a lack of exposure to Brucella spp. at this site during the study period. Despite negative findings in the sampled location, One Health surveillance across multiple species contributes to our understanding of pathogen dynamics and enables targeted interventions to minimize health risks.
Asunto(s)
Brucella , Brucelosis , Ciervos , Sus scrofa , Animales , Argentina/epidemiología , Ciervos/microbiología , Brucelosis/veterinaria , Brucelosis/epidemiología , Perros , Humanos , Brucella/inmunología , Estudios Seroepidemiológicos , Especies Introducidas , Parques Recreativos , Anticuerpos Antibacterianos/sangre , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/microbiología , Enfermedades de los Porcinos/epidemiología , Enfermedades de los Porcinos/microbiología , Animales Salvajes , Porcinos , FemeninoRESUMEN
Brucella abortus (Ba) is a pathogen that survives inside macrophages. Despite being its preferential niche, Ba infects other cells, as shown by the multiple signs and symptoms humans present. This pathogen can evade our immune system. Ba displays a mechanism of down-modulating MHC-I on monocytes/macrophages in the presence of IFN-γ (when Th1 response is triggered) without altering the total expression of MHC-I. The retained MHC-I proteins are located within the Golgi Apparatus (GA). The RNA of Ba is one of the PAMPs that trigger this phenomenon. However, we acknowledged whether this event could be triggered in other cells relevant during Ba infection. Here, we demonstrate that Ba RNA reduced the surface expression of MHC-I induced by IFN-γ in the human bronchial epithelium (Calu-6), the human alveolar epithelium (A-549) and the endothelial microvasculature (HMEC) cell lines. In Calu-6 and HMEC cells, Ba RNA induces the retention of MHC-I in the GA. This phenomenon was not observed in A-549 cells. We then evaluated the effect of Ba RNA on the secretion of IL-8, IL-6 and MCP-1, key cytokines in Ba infection. Contrary to our expectations, HMEC, Calu-6 and A-549 cells treated with Ba RNA had higher IL-8 and IL-6 levels compared to untreated cells. In addition, we showed that Ba RNA down-modulates the MHC-I surface expression induced by IFN-γ on human monocytes/macrophages via the pathway of the Epidermal Growth Factor Receptor (EGFR). So, cells were stimulated with an EGFR ligand-blocking antibody (Cetuximab) and Ba RNA. Neutralization of the EGFR to some extent reversed the down-modulation of MHC-I mediated by Ba RNA in HMEC and A-549 cells. In conclusion, this is the first study exploring a central immune evasion strategy, such as the downregulation of MHC-I surface expression, beyond monocytes and could shed light on how it persists effectively within the host, enduring unseen and escaping CD8+ T cell surveillance.
Asunto(s)
Brucella abortus , Células Endoteliales , Células Epiteliales , Antígenos de Histocompatibilidad Clase I , Interferón gamma , Humanos , Interferón gamma/metabolismo , Interferón gamma/farmacología , Células Endoteliales/metabolismo , Células Endoteliales/microbiología , Células Endoteliales/efectos de los fármacos , Células Endoteliales/inmunología , Células Epiteliales/metabolismo , Células Epiteliales/microbiología , Células Epiteliales/inmunología , Antígenos de Histocompatibilidad Clase I/metabolismo , Antígenos de Histocompatibilidad Clase I/genética , ARN Bacteriano/genética , Línea Celular , Regulación hacia Abajo/efectos de los fármacos , Receptores ErbB/metabolismo , Brucelosis/inmunología , Brucelosis/metabolismo , Brucelosis/microbiología , Brucelosis/genética , Aparato de Golgi/metabolismo , Macrófagos/metabolismo , Macrófagos/inmunología , Macrófagos/microbiología , Monocitos/metabolismo , Monocitos/inmunología , Monocitos/efectos de los fármacosRESUMEN
INTRODUÇÃO: A brucelose humana é uma doença bacteriana de evolução geralmente insidiosa, caracterizada por febre com padrão variável, mal-estar e sudorese noturna. Manifestações comuns incluem perda de peso, artralgia, cefaleia, dor lombar, fadiga, anorexia, mialgia, tosse e alterações emocionais com padrão depressivo. O tratamento é realizado com antibióticos e tem como objetivo a melhora dos sinais e sintomas e evitar a ocorrência de complicações em sistemasórgãos. A melhor evidência disponível aponta que a combinação de aminoglicosídeos com a doxiciclina apresenta as menores taxas de insucesso da terapia. Apenas um antimicrobiano da classe dos aminoglicosídeos está disponível no SUS, o sulfato de estreptomicina, fabricado por um único laboratório oficial e utilizado principalmente no tratamento da tuberculose. Considerando a necessidade de ampliar o arsenal terapêutico para o tratamento da brucelose, a incorporação da gentamicina é uma opção a ser avaliada. PERGUNTA: Qual a eficácia e a segurança da combinação de sulfato de gentamicina e doxiciclina no tratamento da brucelose humana, comparada com a combinação de sulfato de estreptomicina e doxiciclina? EVIDÊNCIAS CLÍNICAS: Foram buscados ensaios clínicos randomizados (ECRs) avaliando desfechos clínicos representativos de sucesso terapêutico com o uso de sulfato de gentamicina combinado à doxiciclina em comparação com sulfato de estreptomicina + doxiciclina, terapia atualmente disponível para mesma indicação no SUS. A busca na literatura foi estruturada através do acrônico PICOS. Foram identificados 2 ECRs que atenderam aos objetivos deste relatório. Não foram observadas diferenças nas taxas de sucesso terapêutico entre a combinação sulfato de gentamicina + doxiciclina vs. sulfato de estreptomicina + doxiciclina (RR: 0,58, IC95%: 0,29 a 1,14). O perfil de segurança avaliado pela taxa de eventos adversos (EA) também foi similar na comparação entre as duas combinações (RR: 1,22; IC95%: 0,83 a 1,80). AVALIAÇÃO ECONÔMICA: Uma análise de custo-efetividade foi realizada utilizando uma modelagem do tipo árvore de decisão. As razões de custo-efetividade para sulfato de estreptomicina e para sulfato de gentamicina, ambos combinados com doxiciclina, foram de, respectivamente, R$ 50,82 e R$ 77,21. A razão de custo-efetividade incremental (ICER) foi de R$ 535,09/por cura. A análise de sensibilidade univariada indicou que a incerteza quanto aos custos do esquema doxiciclina + estreptomicina foi o parâmetro com maior impacto no resultado do ICER. A análise probabilística corrobora com os resultados iniciais, mostrando que o sulfato de gentamicina apresenta maior custo total de tratamento e um benefício clínico levemente superior, cujo efeito é considerado semelhante ao sulfato de estreptomicina. ANÁLISE DE IMPACTO ORÇAMENTÁRIO: Observa-se que a incorporação do sulfato de gentamicina no SUS tem como resultado um incremento de R$59.000,00 em 5 anos, em um cenário conservador. Nos quatro cenários projetados, o impacto orçamentário variou entre uma economia de R$314.000,00 (cenário de baixa incidência) até o incremento de R$454.000,00 (cenário de alta incidência) em 5 anos. Análise de sensibilidade apontou que os parâmetros epidemiológicos (incidência da doença) e populacionais (cobertura no SUS), respectivamente, são os que mais impactam nos valores desta análise. EVIDÊNCIAS INTERNACIONAIS: Até o momento, a incorporação do sulfato de gentamicina para o tratamento de pacientes com brucelose humana ainda não foi avaliada por agências internacionais de ATS pesquisadas. Ressalta-se que nenhuma outra tecnologia foi identificada como já incorporada para tratamento de brucelose por estas agências. MONITORAMENTO DO HORIZONTE TECNOLÓGICO: Não foram detectadas tecnologias no MHT para pacientes com diagnóstico de brucelose humana na forma não localizada. CONSIDERAÇÕES FINAIS: A incorporação de mais um antimicrobiano da classe dos aminoglicosídeos representa ampliação de opções terapêuticas para brucelose humana no Brasil, com o diferencial de oferecer a via de administração endovenosa, em comparação com a via intramuscular, que pode ser uma alternativa mais cômoda para alguns usuários. PERSPECTIVA DO PACIENTE: Foi aberta a Chamada Pública nº 10/2024 para inscrição de participantes para a Perspectiva do Paciente, durante o período de 09/02/2024 a 18/02/2024. Entretanto, não houve inscrições. RECOMENDAÇÃO PRELIMINAR DA CONITEC: Diante do exposto, os membros do Comitê de Medicamentos presentes na 127ª Reunião Extraordinária da Conitec, no dia 07 de março de 2024, recomendaram, por unanimidade, disponibilizar a matéria em consulta pública com parecer preliminar favorável à incorporação ao SUS de sulfato de gentamicina combinado a doxiciclina para o tratamento da brucelose humana. O Comitê considerou para esta recomendação que a possibilidade de mais um medicamento para o tratamento da brucelose humana amplia o arsenal terapêutico e preenche lacunas para o manejo da doença que dispõe atualmente de um antimicrobiano da classe dos aminoglicosídeos, representando vantagens inerentes para este programa estratégico. A implementação da tecnologia foi um ponto destacado para discussão no contexto do PCDT em elaboração, assim como a notificação compulsória dos casos, tema a ser discutido em breve pela área técnica do Ministério da Saúde, no contexto do programa da brucelose humana. CONSULTA PÚBLICA: A consulta pública nº 14 foi realizada entre os dias 09/04/2024 e 29/04/2024 e recebeu uma contribuição de experiência e opinião. A contribuição foi a favor à incorporação, destacando a experiência do profissional com esta tecnologia e outras para o tratamento da brucelose humana. Foi citado como ponto positivo a segurança e conhecimento amplo dos efeitos colaterais do medicamento e como pontos negativos o difícil acesso a esta tecnologia para o tratamento da brucelose humana. A experiência com os medicamentos já padronizados no SUS destaca a eficácia das terapias, mas pontua a existência de recidiva da doença. RECOMENDAÇÃO FINAL DA CONITEC: Após apreciação da contribuição recebida na Consulta Pública, os membros do Comitê de Medicamentos presentes na 129ª Reunião Ordinária da Conitec deliberaram, por unanimidade, recomendar a incorporação do sulfato de gentamicina combinado à doxiciclina para o tratamento da brucelose humana. Foi assinado o Registro de Deliberação nº 898/2024. DECISÃO: Incorporar, no âmbito do Sistema Único de Saúde - SUS, o sulfato de gentamicina combinado à doxiciclina para o tratamento da brucelose humana, publicada no Diário Oficial da União, nº 118, seção 1, página 210, em 21 de junho de 2024.
Asunto(s)
Humanos , Brucelosis/tratamiento farmacológico , Gentamicinas/uso terapéutico , Doxiciclina/uso terapéutico , Sistema Único de Salud , Brasil , Análisis Costo-Beneficio/economía , Combinación de MedicamentosRESUMEN
Neurobrucellosis, caused by Brucella species, is a zoonotic infection that may involve the central nervous system. Although uncommon, it can manifest as a solitary intracranial mass. We report a case of neurobrucellosis in a 25-year-old woman from Peru who presented with headache, weight loss, and right-side hemiparesis and paresthesia. A contrast-enhanced magnetic resonance imaging scan revealed an intracerebral mass in the left temporal lobe. Serum testing subsequently were positive. Brain biopsy demonstrated non-necrotizing granulomas without malignant cells. Neurobrucellosis should be considered in the differential diagnosis of brain space occupying lesions in endemic countries.
Asunto(s)
Brucelosis , Imagen por Resonancia Magnética , Humanos , Femenino , Brucelosis/diagnóstico , Brucelosis/tratamiento farmacológico , Brucelosis/patología , Brucelosis/complicaciones , Adulto , Diagnóstico Diferencial , Neoplasias Encefálicas/diagnóstico por imagen , Neoplasias Encefálicas/diagnóstico , Antibacterianos/uso terapéuticoRESUMEN
The modulation of actin polymerization is a common theme among microbial pathogens. Even though microorganisms show a wide repertoire of strategies to subvert the activity of actin, most of them converge in the ones that activate nucleating factors, such as the Arp2/3 complex. Brucella spp. are intracellular pathogens capable of establishing chronic infections in their hosts. The ability to subvert the host cell response is dependent on the capacity of the bacterium to attach, invade, avoid degradation in the phagocytic compartment, replicate in an endoplasmic reticulum-derived compartment and egress. Even though a significant number of mechanisms deployed by Brucella in these different phases have been identified and characterized, none of them have been described to target actin as a cellular component. In this manuscript, we describe the identification of a novel virulence factor (NpeA) that promotes niche formation. NpeA harbors a short linear motif (SLiM) present within an amphipathic alpha helix that has been described to bind the GTPase-binding domain (GBD) of N-WASP and stabilizes the autoinhibited state. Our results show that NpeA is secreted in a Type IV secretion system-dependent manner and that deletion of the gene diminishes the intracellular replication capacity of the bacterium. In vitro and ex vivo experiments demonstrate that NpeA binds N-WASP and that the short linear motif is required for the biological activity of the protein.IMPORTANCEThe modulation of actin-binding effectors that regulate the activity of this fundamental cellular protein is a common theme among bacterial pathogens. The neural Wiskott-Aldrich syndrome protein (N-WASP) is a protein that several pathogens target to hijack actin dynamics. The highly adapted intracellular bacterium Brucella has evolved a wide repertoire of virulence factors that modulate many activities of the host cell to establish successful intracellular replication niches, but, to date, no effector proteins have been implicated in the modulation of actin dynamics. We present here the identification of a virulence factor that harbors a short linear motif (SLiM) present within an amphipathic alpha helix that has been described to bind the GTPase-binding domain (GBD) of N-WASP stabilizing its autoinhibited state. We demonstrate that this protein is a Type IV secretion effector that targets N-WASP-promoting intracellular survival and niche formation.
Asunto(s)
Proteínas Bacterianas , Factores de Virulencia , Proteína Neuronal del Síndrome de Wiskott-Aldrich , Factores de Virulencia/metabolismo , Factores de Virulencia/genética , Proteína Neuronal del Síndrome de Wiskott-Aldrich/metabolismo , Proteína Neuronal del Síndrome de Wiskott-Aldrich/genética , Proteínas Bacterianas/metabolismo , Proteínas Bacterianas/genética , Humanos , Sistemas de Secreción Tipo IV/metabolismo , Sistemas de Secreción Tipo IV/genética , Animales , Ratones , Unión Proteica , Brucella/metabolismo , Brucella/genética , Brucella/patogenicidad , Secuencias de Aminoácidos , Actinas/metabolismo , Brucelosis/microbiología , Macrófagos/microbiología , Interacciones Huésped-PatógenoRESUMEN
BACKGROUND: Antibiotic prophylaxis to prevent brucellosis after accidental exposure to Brucella is an important topic in public health. This study aimed to systematically review the efficacy of antibiotic prophylaxis following accidental exposure to Brucella in preventing human brucellosis disease. METHODS: The study protocol was registered in PROSPERO (CRD42023456812). The outcomes included the incidence of brucellosis disease, adverse events rate, and antibiotic prophylaxis adherence. A comprehensive literature search, conducted until 20 November, 2023, involved Medline, Embase, Cochrane Library, and LILACS databases. Descriptive analysis and meta-analysis using R software were performed, risk of bias was assessed using JBI Critical appraisal tools, and certainty of evidence was assessed using the GRADE tool. RESULTS: Among 3102 initially identified records, eight studies involving 97 individuals accidentally exposed, all focused on high-risk accidental exposure to Brucella in laboratory settings, were included in the review. All studies reported the prophylactic treatment comprising doxycycline at a dosage of 100 mg twice daily, combined with rifampicin at 600 mg, both administered over 21 days. Prophylaxis adherence was reported in 86% of cases, and incidence of brucellosis post-treatment was 0.01. Adverse events, mainly gastrointestinal, occurred in 26% of cases. Critical appraisal revealed limitations in reporting demographics and clinical information. The certainty of evidence was rated as 'very low,' emphasising the need for caution in interpreting the observed outcomes due to study design constraints and the absence of comparative groups. CONCLUSIONS: PEP is an alternative practice reported in the literature, used in accidents with high-risk exposure to Brucella. The currently available evidence of the efficacy of antibiotic prophylaxis is insufficient to support a recommendation for or against the widespread use of antibiotic prophylaxis, so caution is needed in interpreting results due to the very low certainty of evidence, primarily stemming from case series and lack of comparative groups.
Asunto(s)
Antibacterianos , Profilaxis Antibiótica , Brucelosis , Brucelosis/prevención & control , Humanos , Antibacterianos/uso terapéutico , Doxiciclina/uso terapéutico , Rifampin/uso terapéutico , BrucellaRESUMEN
Animal hoarding disorder (AHD) is classified as a psychiatric obsessive-compulsive condition characterized by animal accumulation and often accompanied by unsanitary conditions and animal cruelty. Although AHD may increase pathogen transmission and spread, particularly for zoonotic diseases, human and dog exposure in such cases has yet to be fully established. Accordingly, this study aimed to assess Brucella canis in 19 individuals with AHD (11 households) and their 264 dogs (21 households) in Curitiba, the eighth largest city in Brazil, with approximately 1.8 million habitants. Anti-B. canis antibodies were detected by the 2-mercaptoethanol microplate agglutination test (2ME-MAT) and by a commercial lateral flow immunoassay (LFIA), while molecular detection of previously positive seropositive samples was performed by conventional PCR. Although all the human samples were 2ME-MAT negative, 12/264 (4.5%, 95% Confidence Interval: 2.0-7.0%) dog samples were 2ME-MAT and LFIA positive, with 2ME-MAT titers ranging from 20 to 640. At least one dog in 4/21 (19.0%, 95% CI: 2.0-46.0%) households was seropositive. Despite the absence of seropositivity in individuals with AHD and the comparatively low seroprevalence in dogs, B. canis circulation and outbreaks should be considered in such human populations due to the high burden and recurrent character of B. canis exposure in high-density dog populations and the constant introduction of susceptible animals.
Asunto(s)
Brucella canis , Brucelosis , Enfermedades de los Perros , Trastorno de Acumulación , Animales , Perros , Humanos , Brucella canis/genética , Brucelosis/diagnóstico , Brucelosis/epidemiología , Brucelosis/veterinaria , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/epidemiología , Salud Única , Estudios SeroepidemiológicosRESUMEN
Introduction: The lncRNAs (long non-coding RNAs) are the most diverse group of non-coding RNAs and are involved in most biological processes including the immune response. While some of them have been recognized for their influence on the regulation of inflammatory activity, little is known in the context of infection by Brucella abortus, a pathogen that presents significant challenges due to its ability to manipulate and evade the host immune system. This study focuses on characterize the expression profile of LincRNA-cox2, Lethe, lincRNA-EPS, Malat1 and Gas5 during infection of macrophages by B. abortus. Methods: Using public raw RNA-seq datasets we constructed for a lncRNA expression profile in macrophages Brucella-infected. In addition, from public RNA-seq raw datasets of RAW264.7 cells infected with B. abortus we constructed a transcriptomic profile of lncRNAs in order to know the expression of the five immunomodulating lncRNAs studied here at 8 and 24 h post-infection. Finally, we performed in vitro infection assays in RAW264.7 cells and peritoneal macrophages to detect by qPCR changes in the expression of these lncRNAs at first 12 hours post infection, a key stage in the infection cycle where Brucella modulates the immune response to survive. Results: Our results demonstrate that infection of macrophages with Brucella abortus, induces significant changes in the expression of LincRNA-Cox2, Lethe, LincRNA-EPS, Gas5, and Malat1. Discussion: The change in the expression profile of these immunomodulatory lncRNAs in response to infection, suggest a potential involvement in the immune evasion strategy employed by Brucella to facilitate its intracellular survival.
Asunto(s)
Brucelosis , ARN Largo no Codificante , Animales , Ratones , Brucella abortus/genética , ARN Largo no Codificante/genética , ARN Largo no Codificante/metabolismo , Ciclooxigenasa 2/metabolismo , MacrófagosRESUMEN
The present study evaluates the effects of vaccination with Brucella melitensis strains Rev 1 ΔeryCD and Rev 1 on the reproductive system of male goats. Three groups, each of them consisting of 15 six-month-old brucellosis-free male goats, were studied. The first group was vaccinated with the Rev 1 ΔeryCD strain, the second group received Rev 1 and the third group was inoculated with sterile physiological saline solution. The dose of both strains was of 1×109CFU/ml. Over the course of the five months of this study, three males from each group were euthanized every month. Their reproductive tracts, spleens, and lymph nodes were collected to analyze serology, bacteriology PCR, histology, and immunohistochemistry. Results show that vaccination with B. melitensis strains Rev 1 ΔeryCD and Rev 1 does not harm the reproductive system of male goats. Strain B. melitensis Rev 1 ΔeryCD displayed a lower capacity to colonize the reproductive tract than strain Rev 1, which was attributed to its limited catabolic action toward erythritol.
Asunto(s)
Vacuna contra la Brucelosis , Brucella melitensis , Brucelosis , Cabras , Animales , Masculino , Brucella melitensis/inmunología , Brucelosis/prevención & control , Brucelosis/veterinaria , Brucelosis/microbiología , Vacuna contra la Brucelosis/inmunología , Vacuna contra la Brucelosis/administración & dosificación , Vacunación , Genitales Masculinos/microbiología , Vacunas BacterianasRESUMEN
BACKGROUND: Brucellosis, a widely spread zoonotic disease, poses significant diagnostic challenges due to its non-specific symptoms and underreporting. Timely and accurate diagnosis is crucial for effective patient management and public health control. However, a comprehensive comparative review of available diagnostic tests is lacking. METHODOLOGY/PRINCIPAL FINDINGS: This systematic review addressed the following question: 'What is the accuracy of the available tests to confirm human brucellosis?' Two independent reviewers examined articles published up to January 2023. The review included original studies reporting symptomatic patients with brucellosis suspicion, through any index test, with sensitivity and/or specificity as outcomes. As exclusion criteria were considered: sample size smaller than 10 patients, studies focusing on complicated brucellosis, and those lacking essential information about index or comparator tests. Sensitivity and specificity were assessed, with consideration for the index test, and 'culture' and 'culture and standard tube agglutination test (SAT)' were used as reference standards. Bias assessment and certainty of evidence were carried out using the QUADAS-2 and GRADE tools, respectively. A total of 38 studies reporting diagnostic test performance for human brucellosis were included. However, the evidence available is limited, and significant variability was observed among studies. Regarding the reference test, culture and/or SAT are deemed more appropriate than culture alone. Rose Bengal, IgG/IgM ELISA, and PCR exhibited equally high performances, indicating superior overall diagnostic accuracy, with very low certainty of the evidence. CONCLUSIONS/SIGNIFICANCE: This systematic review underscores the potential of the Rose Bengal test, IgG/IgM ELISA, and PCR as promising diagnostic tools for brucellosis. However, the successful implementation and recommendations for their use should consider the local context and available resources. The findings highlight the pressing need for standardization, improved reporting, and ongoing advancements in test development to enhance the accuracy and accessibility of brucellosis diagnosis.
Asunto(s)
Brucelosis , Sensibilidad y Especificidad , Brucelosis/diagnóstico , Humanos , Brucella/inmunología , Brucella/aislamiento & purificación , Pruebas Diagnósticas de Rutina/métodos , Pruebas Diagnósticas de Rutina/normas , Pruebas de AglutinaciónRESUMEN
BACKGROUND: Human brucellosis is a neglected, re-emerging, and endemic zoonosis in many countries. The debilitating and disabling potential of the disease is a warning about its morbidity, generating socioeconomic impact. This review aims to update the current evidence on the efficacy and safety of therapeutic options for human brucellosis using the network meta-analysis (NMA). METHODOLOGY: A systematic search was conducted in four different databases by independent reviewers to assess overall therapy failure, adverse events, and time to defervescence associated with different therapies. Randomized clinical trials (RCTs) evaluating any therapeutic drug intervention were selected, excluding non-original studies or studies related to localized forms of the disease or with less than 10 participants. Data were analyzed by frequentist statistics through NMA by random effects model. The risk of bias and certainty of evidence was assessed, this review was registered at PROSPERO. RESULTS: Thirty-one (31) RCTs involving 4167 patients were included. Three networks of evidence were identified to evaluate the outcomes of interest. Triple therapy with doxycycline + streptomycin + hydroxychloroquine for 42 days (RR: 0.08; CI 95% 0.01-0.76) had a lower failure risk than the doxycycline + streptomycin regimen. Doxycycline + rifampicin had a higher risk of failure than doxycycline + streptomycin (RR: 1.96; CI 95% 1.27-3.01). No significant difference was observed between the regimens when analyzing the incidence of adverse events and time to defervescence. In general, most studies had a high risk of bias, and the results had a very low certainty of evidence. CONCLUSIONS: This review confirmed the superiority of drugs already indicated for treating human brucellosis, such as the combination of doxycycline and aminoglycosides. The association of hydroxychloroquine to the dual regimen was identified as a potential strategy to prevent overall therapy failure, which is subject to confirmation in future studies.
Asunto(s)
Antibacterianos , Brucelosis , Doxiciclina , Quimioterapia Combinada , Metaanálisis en Red , Estreptomicina , Humanos , Brucelosis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Antibacterianos/efectos adversos , Doxiciclina/uso terapéutico , Doxiciclina/efectos adversos , Estreptomicina/uso terapéutico , Hidroxicloroquina/uso terapéutico , Hidroxicloroquina/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto , Rifampin/uso terapéutico , Rifampin/efectos adversos , Resultado del TratamientoRESUMEN
Introduction: Guanylate-binding proteins (GBPs) are produced in response to pro-inflammatory signals, mainly interferons. The most studied cluster of GBPs in mice is on chromosome 3. It comprises the genes for GBP1-to-3, GBP5 and GBP7. In humans, all GBPs are present in a single cluster on chromosome 1. Brucella abortus is a Gram-negative bacterium known to cause brucellosis, a debilitating disease that affects both humans and animals. Our group demonstrated previously that GBPs present on murine chromosome 3 (GBPchr3) is important to disrupt Brucella-containing vacuole and GBP5 itself is important to Brucella intracellular LPS recognition. In this work, we investigated further the role of GBPs during B. abortus infection. Methods and results: We observed that all GBPs from murine chromosome 3 are significantly upregulated in response to B. abortus infection in mouse bone marrow-derived macrophages. Of note, GBP5 presents the highest expression level in all time points evaluated. However, only GBPchr3-/- cells presented increased bacterial burden compared to wild-type macrophages. Brucella DNA is an important Pathogen-Associated Molecular Pattern that could be available for inflammasome activation after BCV disruption mediated by GBPs. In this regard, we observed reduced IL-1ß production in the absence of GBP2 or GBP5, as well as in GBPchr3-/- murine macrophages. Similar result was showed by THP-1 macrophages with downregulation of GBP2 and GBP5 mediated by siRNA. Furthermore, significant reduction on caspase-1 p20 levels, LDH release and Gasdermin-D conversion into its mature form (p30 N-terminal subunit) was observed only in GBPchr3-/- macrophages. In an in vivo perspective, we found that GBPchr3-/- mice had increased B. abortus burden and higher number of granulomas per area of liver tissue, indicating increased disease severity. Discussion/conclusion: Altogether, these results demonstrate that although GBP5 presents a high expression pattern and is involved in inflammasome activation by bacterial DNA in macrophages, the cooperation of multiple GBPs from murine chromosome 3 is necessary for full control of Brucella abortus infection.
Asunto(s)
Brucelosis , Proteínas de Unión al GTP , Animales , Ratones , Brucella abortus/genética , Brucelosis/microbiología , Proteínas Portadoras/metabolismo , ADN Bacteriano , Inflamasomas/genética , Inflamasomas/metabolismo , Proteínas de Unión al GTP/genéticaRESUMEN
Members of the genus Brucella are the causative agents of brucellosis, a worldwide zoonosis affecting wild and domestic animals and humans. These facultative intracellular pathogens cause long-lasting chronic infections by evolving sophisticated strategies to counteract, evade, or subvert host bactericidal mechanisms in order to establish a secure replicative niche necessary for their survival. In this review, we present recent findings on selected Brucella effectors to illustrate how this pathogen modulates host cell signaling pathways to gain control of the vacuole, promote the formation of a safe intracellular replication niche, alter host cell metabolism to its advantage, and exploit various cellular pathways to ensure egress from the infected cell.
Asunto(s)
Brucella , Brucelosis , Animales , Humanos , Brucella/genética , Interacciones Huésped-Patógeno , VacuolasRESUMEN
Our study explored the patterns of bovine brucellosis dissemination in Minas Gerais state, Brazil, by examining data on passive surveillance of bovine brucellosis cases from the Instituto Mineiro de Agropecuaria (IMA) (Animal Health Authority), as well as cattle population and bovine brucellosis testing, from 2011 to 2018 by means of a spatiotemporal analysis. We plotted cases, populations and testing distributions and performed spatial autocorrelation (Moran's I test) and local indicators of spatial autocorrelation (LISA) analyses. Moreover, we assessed the correlation of the spatial distribution and the compiled data (brucellosis cases, cattle populations, and brucellosis testing) by Lee's test. Our results showed that bovine brucellosis cases occurred mainly in the Triângulo Mineiro, Alto Paranaíba and Northwest regions, which reported cases in all analyzed years (2011 to 2018). The cattle population of Minas Gerais was concentrated in the same regions as bovine brucellosis cases, and the performed tests through the analyzed years (2011 to 2018). Moran's I test results of the case data showed significant spatial autocorrelation in 2011, 2015 and 2018 (p value < 0.05), and from 2011 to 2018, the population and testing data were also significant in Moran's I test (p value < 0.01). The results of cluster analysis (LISA) of cases showed clusters mainly in the Triângulo Mineiro, Alto Paranaíba, Northwest and South regions in 2011, 2015 and 2018. The local clusters for cattle populations and brucellosis testing were also observed in the same regions as bovine brucellosis cases in all years (2011 to 2018). The correlation results between clusters (Lee's test) were 0.22 (p value < 0.01) in 2011, 0.15 (p value < 0.01) in 2015 and 0.43 (p value <0.01) in 2018 between cases and populations, and 0.25 (p value <0.01) in 2011, 0.14 (p value <0.01) in 2015 and 0.38 (p value < 0.01) in 2018 for testing and cases. Therefore, our results showed that brucellosis cases were distributed together with cattle populations and brucellosis testing data, indicating that brucellosis in cattle in Minas Gerais state is being identified where there are more animals and where more tests are performed.
Asunto(s)
Brucelosis Bovina , Brucelosis , Enfermedades de los Bovinos , Bovinos , Animales , Brasil/epidemiología , Brucelosis Bovina/epidemiología , Brucelosis/epidemiología , Brucelosis/veterinaria , Análisis Espacio-Temporal , Análisis Espacial , Enfermedades de los Bovinos/epidemiologíaRESUMEN
INTRODUCTION: Aminoglycosides are vital antibiotics for treating Brucella infections, because they interfere with bacterial protein production and are often combined with other antibiotics. They are cost-effective, have fewer side effects, and can penetrate biofilms. The prevalence of brucellosis has increased in recent years, increasing the need for effective treatments. In addition, the emergence of multidrug-resistant Brucella strains has highlighted the need for an updated and comprehensive understanding of aminoglycoside resistance. This systematic review aimed to provide a comprehensive overview of the global prevalence of aminoglycoside resistance in B. melitensis and B. abortus. METHODS: A systematic search of online databases was conducted and eligible studies met certain criteria and were published in English. Quality assessment was performed using the JBI Checklist. A random-effects model was fitted to the data, and meta-regression, subgroup, and outlier/influential analyses were performed. The analysis was performed using R and the metafor package. RESULTS: The results of this systematic review and meta-analysis suggested that the average prevalence rates of streptomycin, gentamicin, and amikacin resistance were 0.027 (95% confidence interval [CI], 0.015-0.049), 0.023 (95% CI, 0.017-0.032), and 0.008 (95% CI, 0.002-0.039), respectively. The prevalence of streptomycin resistance was higher in the unidentified Brucella group than in the B. abortus and B. melitensis groups (0.234, 0.046, and 0.017, respectively; p < 0.02). The prevalence of gentamicin resistance increased over time (r = 0.064; 95% CI, 0.018 to 0.111; p = 0.007). The prevalence of resistance did not correlate with the quality score for any antibiotic. Funnel plots showed a potential asymmetry for streptomycin and gentamicin. These results suggest a low prevalence of antibiotic resistance in the studied populations. CONCLUSION: The prevalence of aminoglycoside resistance in B. melitensis and B. abortus was low. However, gentamicin resistance has increased in recent years. This review provides a comprehensive and updated understanding of aminoglycoside resistance in B. melitensis and B. abortus.
Asunto(s)
Aminoglicósidos , Antibacterianos , Brucella abortus , Brucella melitensis , Brucelosis , Aminoglicósidos/farmacología , Brucella abortus/efectos de los fármacos , Brucella abortus/genética , Brucella abortus/aislamiento & purificación , Antibacterianos/farmacología , Brucelosis/microbiología , Brucelosis/epidemiología , Brucella melitensis/efectos de los fármacos , Brucella melitensis/aislamiento & purificación , Brucella melitensis/genética , Humanos , Prevalencia , Farmacorresistencia Bacteriana , Pruebas de Sensibilidad Microbiana , AnimalesRESUMEN
Brucellosis, caused by Brucella bacteria, is a common zoonotic infectious disease with various clinical manifestations in humans and animals. The disease is endemic in human and ruminant populations in Iran, with a particular prevalence in areas where humans have close interactions with livestock. Since domestic animals serve as the primary reservoir for brucellosis, this study aimed to identify the presence of Brucella spp. among aborted small ruminants in southeast Iran. Between 2021 and 2022, aborted fetuses of small ruminants (46 sheep and 4 goats) were collected from Zarand County in the Kerman province. Swab samples from the abomasum contents of these fetuses were obtained and subjected to DNA extraction. The samples were then tested for Brucella spp. detection using the polymerase chain reaction (PCR) method. Out of the 50 aborted fetuses examined, Brucella spp. was detected in 15 (30%) specimens, comprising 13 (28%) sheep and 2 (50%) goats. Species typing revealed the presence of Brucella ovis (6 sheep and 1 goat), Brucella melitensis (6 sheep), and Brucella abortus (1 sheep) among the positive specimens. This cross-sectional study highlights the high prevalence of various Brucella species in samples from small ruminant abortions in southeast Iran. Additionally, the identified Brucella species were not limited to their primary host livestock. These indicated potential cross-species transmission among small ruminants.
Asunto(s)
Brucella melitensis , Brucelosis , Enfermedades de las Cabras , Enfermedades de las Ovejas , Humanos , Embarazo , Femenino , Animales , Ovinos , Irán/epidemiología , Estudios Transversales , Rumiantes , Brucelosis/epidemiología , Brucelosis/veterinaria , Brucelosis/diagnóstico , Brucella melitensis/genética , Cabras/microbiología , Ganado , Enfermedades de las Ovejas/microbiología , Enfermedades de las Cabras/epidemiología , Enfermedades de las Cabras/microbiologíaRESUMEN
Background: Although Brucella abortus, Brucella suis, and Brucella canis may infect humans and dogs worldwide, no study to date has assessed and compared owners and their dogs between island and mainland seashore areas. Materials and Methods: Accordingly, the study herein has applied serological tests, including Microplate Agglutination Test with 2-Mercaptoethanol, immunochromatographic assay, and Rose Bengal Test, and a Brucella genus-specific PCR assay to 195 owners and their 148 dogs living on 1 mainland seashore area and three nearby oceanic islands of southern Brazil. Results: No seropositivity to B. abortus and B. suis was detected in owner or dog sera. Anti-B. canis seropositivity was observed in 3/148 (2.0%) dogs, but no owner sample was seropositive to B. canis. In addition, all blood samples from both owners and dogs were negative on Brucella genus-specific PCR assay. Conclusions: The seropositive dogs were not related and lived on the seashore mainland area of Guaraqueçaba city. The absence of seropositivity on the islands and the low seropositivity on the seashore mainland could be attributed to geographic isolation, and suggest the low impact of the disease in the region. Despite being a zoonotic disease, brucellosis by B. canis is not included in the National Program for Control and Eradication of Brucellosis, and its diagnosis and notification are not mandatory. The presence of seropositive dogs highlights the risk to human health and the importance of epidemiological surveillance actions in the region, as well as the need for the implantation of preventive measures to avoid the transmission of the pathogen.
Asunto(s)
Brucella canis , Brucelosis , Enfermedades de los Perros , Humanos , Perros , Animales , Brasil/epidemiología , Enfermedades de los Perros/epidemiología , Brucelosis/epidemiología , Brucelosis/veterinaria , Brucelosis/diagnóstico , Brucella canis/genética , Brucella abortusRESUMEN
The direct methods for diagnosis of bovine brucellosis have several limitations, therefore serological tests are the basis for the diagnosis of the disease. However, a meta-analysis estimating the diagnostic sensitivity (DSe) and diagnostic specificity (DSp) on the main tests used in bovine brucellosis control programs worldwide has not been performed. This systematic review and meta-analysis aimed to estimate the DSe, DSp and thereby accuracy of serological tests individually used in the diagnosis of bovine brucellosis. The databases CABI, Cochrane Library, PubMed/MEDLINE, SciELO, Scopus and Web of Science were used to select articles. The search resulted in 5308 studies, of which 71 were selected for systematic review using quality assessment tools and 65 studies were included in the meta-analysis. For the meta-analysis, 178 assays and 11 different serological tests were considered. To estimate DSe and DSp of the tests, studies were divided according to animal selection for the studies: (1) studies that carried out a random or consecutive selection of participants (noncasecontrol studies) and (2) all studies, including casecontrol studies. Considering only the non-case-control studies to estimate the DSe, the tests that exhibited the best and worst performance were the iELISA test (indirect enzyme immunoassay - bacterial suspension as antigen - BS) (96.5%, 95% CI: 94.1-97.9%) and 2ME (2- mercaptoethanol test) (85.0%, 95% CI: 79.6-89.1%), respectively; while for DSp, the FPA (fluorescence polarization assay) (99, 7%, 95% CI: 99.5-99.8%) and PCFIA tests (protein concentration fluorescence immunoassay) (78.5%, 95% CI: 70.0-85.1%) showed better and worse performance, respectively. Overall, our results showed an overestimation in the DSe and DSp of the eleven serological tests assessed when casecontrol studies were included in the meta-analysis, which is a concern considering its impacts on the time and costs associated with populational diagnosis of the diseases, since several of these tests are routinely used in the control and eradication programs of bovine brucellosis worldwide. Furthermore, the tests that exhibited the best DSe and DSp, iELISA (BS) and FPA, respectively, are relatively easy to perform and interpret and the test which showed the best overall accuracy was FPA.